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Summary  The  use  of  pharmacological  lipid-lowering  intervention  in  individuals  with  hyper-
cholesterolaemia  and  known  cardiovascular  disease  or  diabetes/chronic  kidney  disease  is  well
established.  Current  European  Society  of  Cardiology  guidelines  recommend  immediate  initiation
of drugs  in  adjunct  to  lifestyle  intervention  in  these  patients  at  high  or  very  high  cardiovascular
risk. In  these  clinical  settings,  statins  are  generally  chosen  as  the  ﬁrst-choice  drug  intervention,
in consideration  of  the  robust  evidence  showing  a  reduction  in  all-cause  mortality  and  major
adverse cardiac  events  (MACE).  In  contrast,  primary  prevention  with  statins,  even  in  the  sub-cholesterol;
High  blood  pressure
set of  patients  at  high-risk  of  cardiovascular  events,  is  not  well  implemented.  This  might  be
related to  a  lack  of  public  awareness  regarding  the  actual  risk  associated  with  prolonged  expo-
sure to  high  concentrations  of  low-density  lipoprotein  cholesterol  (LDL-C)  and  uncertainties  in
the clinical  evidence  coming  from  the  earliest  trials  in  this  patient  subset.  However,  recent
observational  studies  suggest  that  lowering  LDL-C  earlier  in  life  and  for  a  longer  duration  can
Abbreviations: ACS, Acute coronary syndrome; CI, Conﬁdence interval; CHD, Coronary heart disease; CKD, Chronic kidney disease;
VD, Cardiovascular disease; HBP, High blood pressure; LDL, Low-density lipoprotein; LDL-C, Low-density lipoprotein cholesterol; MACE,
ajor adverse cardiac events; NNH, Number needed to harm; NNT, Number needed to treat; OR, Odds ratio; PCSK9, Proprotein convertase
ubtilisin/kexin type 9; RCT, Randomized clinical trial; RR, Relative risk; RRR, Relative risk reduction.
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substantially  decrease  the  burden  of  cardiovascular  disease  and  mortality.  Moreover,  results
from recent  well-conducted  large  meta-analyses  of  randomized  clinical  trials  showed  that  pri-
mary prevention  with  statins  reduced  all-cause  mortality  by  14%  and  MACE  by  >  20%  —  ﬁndings
similar to  those  observed  for  the  use  of  statins  in  secondary  prevention.  Recently  published
American Heart  Association/American  College  of  Cardiology  guidelines  on  the  treatment  of
blood cholesterol  emphasize  that  primary  prevention  using  high-dose  statins  in  individuals  with
LDL-C ≥  190  mg/dL  induces  a  beneﬁt  in  atherosclerotic  cardiovascular  risk  reduction  that  clearly
exceeds the  potential  for  adverse  effects.  We  aim  in  this  review  to  discuss  the  new  data  that
advocate the  use  of  statins  in  primary  prevention  earlier  and  more  frequently,  putting  the
efﬁcacy evidence  into  perspective  with  new  insights  in  terms  of  safety  issues.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Le  recours  à  un  traitement  médicamenteux  hypolipémiant  chez  des  individus  présen-
tant une  hypercholestérolémie  et  une  pathologie  cardiovasculaire  connue  (CVD)  ou  un  diabète
ou encore  une  maladie  rénale  chronique  (MRC)  est  bien  établi.  Les  recommandations  actuelles
de l’ESC  préconisent  l’initiation  immédiate  d’un  traitement  médicamenteux  en  complément
d’une intervention  relative  au  mode  de  vie,  chez  ces  patients  à  haut  risque  ou  très  haut  risque
cardiovasculaire.  Dans  ces  contextes  cliniques,  les  statines  sont  en  général  considérées  comme
le traitement  de  première  intention  sur  la  base  de  données  montrant  une  réduction  de  la
mortalité toutes  causes  confondues  et  des  événements  cardiovasculaires  majeurs  (MACE).  En
revanche, la  prévention  primaire  par  les  statines,  même  dans  le  sous-groupe  de  patients  à  haut
risque d’événements  cardiovasculaires,  n’est  pas  bien  appliquée.  Ceci  pourrait  être  lié  à  un
manque de  sensibilisation  du  public  en  ce  qui  concerne  le  risque  réel  associé  à  une  exposi-
tion prolongée  à  un  taux  élevé  de  cholestérol  lié  aux  lipoprotéines  de  faible  densité  (LDL-C)
et aux  incertitudes  dans  la  validité  des  preuves  cliniques  émanant  des  premiers  essais  dans  ce
sous-groupe  de  patients.  Cependant,  des  études  observationnelles  récentes  suggèrent  que  la
diminution  du  taux  de  LDL-C  à  un  âge  précoce  et  sur  une  durée  plus  longue  peut  diminuer  de
fac¸on notable  l’impact  des  maladies  cardiovasculaires  et  la  mortalité.  Par  ailleurs,  les  résul-
tats issus  de  méta-analyses  récentes  et  rigoureuses,  conduites  à  grande  échelle  à  partir  d’essais
cliniques randomisés,  ont  montré  que  la  prévention  primaire  par  des  statines  réduit  la  mortalité
toutes causes  confondues  de  14  %  et  les  MACE  de  plus  de  20  %,  soit  des  proportions  comparables
à celles  observées  lors  de  l’utilisation  des  statines  en  prévention  secondaire.  Les  recommanda-
tions AHA/ACC  publiées  récemment  sur  la  prise  en  charge  de  l’hypercholestérolémie  soulignent
le fait  que  la  prévention  primaire  par  de  fortes  doses  de  statines  chez  des  individus  avec  un
LDL-C ≥  190  mg/dL  induit  un  bénéﬁce  dans  la  réduction  du  risque  cardiovasculaire  athéroscléro-
tique qui  excède  clairement  le  risque  de  survenue  d’événements  indésirables.  Le  but  de  cette
revue est  de  faire  état  des  nouvelles  données  qui  plaident  en  faveur  de  l’utilisation  des  statines
en prévention  primaire,  de  manière  plus  précoce  et  plus  fréquente  que  celle  appliquée  actuel-
lement, en  mettant  en  perspective  les  preuves  d’efﬁcacité  et  les  nouvelles  données  relatives
à la  tolérance.
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Introduction
Ischaemic  heart  disease  and  stroke  were  the  leading  causes
of  death  in  2010,  with  a  relative  increase  in  rates  compared
with  1990  of  35%  and  26%,  respectively,  and  they  are  still
ranked  the  ﬁrst  and  second  causes  of  death  worldwide;  this
represents  approximately  one  in  four  deaths  worldwide  for
the  two  diseases  combined  [1].
When  focusing  on  western  countries,  such  as  the  USA,
an  opposite  trend  is  observed,  with  declining  rates  of
death  attributable  to  cardiovascular  diseases  (CVDs)  in
the  past  decade  [2],  although  they  still  account  for  one
in  every  three  deaths  in  the  USA.  In  Europe,  the  same
trends  are  noted,  with  deaths  due  to  cardiovascular  dis-
ease  and  coronary  heart  disease  (CHD),  accounting  for
46%  and  20%  of  deaths,  respectively,  although  there  are
d
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ubstantial  inequalities  between  countries  [3]. In  parallel,
e  have  observed  a  decline  in  the  prevalence  of  some
odiﬁable  risk  factors,  such  as  cigarette  smoking  rate,
ncontrolled  high  blood  pressure  (HBP)  and  average  low-
ensity  lipoprotein  cholesterol  (LDL-C)  concentration  in  the
opulation,  concurrent  with  improvements  in  lifestyle  and
harmacological  interventions.  For  instance,  regarding  HBP
ontrol,  when  comparing  data  from  the  1988—1994  National
ealth  and  Nutrition  Examination  Survey  in  the  USA  [4]  and
he  2007—2008  period,  awareness  improved  from  69.1%  to
0.7%,  the  use  of  anti-hypertensive  drugs  increased  from
4.0%  to  73.5%  and  the  ratio  of  controlled/treated  HBP
ates  improved  from  50.6%  to  72.3%  [5].  In  addition,  nowa-
ays,  most  higher  risk  patients  with  HBP  and  co-morbidities
eceive  anti-hypertensive  agents  (88.3%  use  in  HBP  with
hronic  kidney  disease  [CKD],  93.4%  use  in  concomitant
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iabetes  and  94.0%  use  in  patients  with  CVD  in  2010);
hese  rates  are  higher  than  for  HBP  without  co-morbidities
67.8%)  [6].  Regarding  the  LDL-C  rate,  interesting  recent
ata  from  the  French  MONICA  registry  show  that  treat-
ent  with  statins  in  primary  prevention  is  able  to  change
he  initial  presentation  of  acute  coronary  syndrome  (ACS),
ith  more  non-ST-segment  elevation  myocardial  infarction
nd  unstable  angina  and  less  ST-segment  elevation  myocar-
ial  infarction  [7]  in  comparison  with  patients  not  treated
ith  statins  before  the  ﬁrst  manifestation  of  acute  CHD.
he  objectives  of  this  review  are  to  summarize  the  clini-
al  research  data  supporting  primary  prevention  with  statins
nd  to  analyse  gaps  in  actual  practice.
hy focus on primary prevention with
tatins in high-risk groups?
n  contrast  to  the  marked  improvement  in  HBP  awareness
nd  treatment  rates  in  high-risk  patients,  the  adoption
f  lipid-lowering  drugs  seems  to  lag  behind  in  a  sub-
tantial  proportion  of  patients  with  hypercholesterolaemia
nd  co-morbidities.  In  the  USA,  in  patients  with  diabetes,
pproximately  60%  do  not  receive  a  lipid-lowering  agent
8],  and  in  patients  with  CKD,  fewer  than  one  third  receive
ipid-lowering  drugs  and  only  40%  are  at  LDL-C  goal  [9].
In  Europe,  we  observed  encouraging  trends  towards  a
ecrease  in  mean  LDL-C  concentrations  [10—12],  but  we  also
oticed  that  LDL-C  management  was  worryingly  suboptimal
n  high-risk  groups.  For  instance,  in  the  French  MONA  LISA
tudy  [13],  only  42%  of  patients  at  high-  or  very  high-risk,
ccording  to  the  latest  European  guidelines  [14],  received
ipid-lowering  therapy.  Although  a  slight  majority  of  patients
t  very  high-risk  (58%)  actually  beneﬁt  from  a  lipid-lowering
gent,  the  vast  majority  (72%)  of  those  eligible  for  primary
revention  (high-risk  group  with  multiple  co-morbidities  but
o  CVD)  are  excluded  from  the  recommended  therapy  [13].
We  also  observed  in  a  large  European  Union/Canadian
egistry  [15,16]  that  the  low-density  lipoprotein  (LDL)  con-
rol  rate  was  not  correlated  to  the  actual  risk  level.  The
ontrol  rate  averaged  approximately  50%  in  all  patients,
arying  slightly  from  44%  in  patients  with  low  European  Soci-
ty  of  Cardiology  scores  to  58%  in  very  high-risk  CVD  patients
Table  1)  [16].In  France,  results  from  a  study  conducted  in  a  more  spe-
iﬁc  population  of  patients  aged  >  45  years  who  had  been
reated  with  statins  for  >  3  months,  the  control  rate  was
orse  in  the  higher  risk  group  (52%  not  at  goal)  compared
c
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Table  1  Proportion  of  patientsa whose  lipid  concentrations  w
All
(n  =  21,797)
High-risk
patients
(n  =  17,583)
TC  not  at  goal  (%)  54.4  52.1  
LDL-C  not  at  goal  (%)  48.5  46.8  
CVD: cardiovascular disease; ESC: European Society of Cardiology; LDL
a Patients were recruited from 2954 treatment centres in 11 Europ
Germany, Austria, Ireland, United Kingdom, France, Portugal and SpainE.  Bruckert,  J.  Ferrières
ith  in  the  overall  population  of  statin  users  (38%  not  at
oal)  [17].
Overall,  the  key  ﬁndings  of  these  observational  studies
uggest  that  the  management  of  high  LDL-C  is  particularly
imited  in  highest  risk  groups  eligible  for  primary  prevention
ompared  with  in  those  treated  for  secondary  prevention
nd  lower-risk  groups.
hat is the indirect evidence in favour of
arlier initiation and prolonged
DL-lowering interventions?
n  a  recently  published  meta-analysis  of  312,321  subjects,
he  researchers  used  a  Mendelian  randomization  approach
o  estimate  the  clinical  beneﬁt  of  lowering  LDL  early  in  life.
he  authors  used,  as  a  proxy  for  a  treatment  that  would
ecrease  LDL-C  beginning  at  birth,  the  inherited  allocation
o  protective  genotypes  (for  nine  single  nucleotide  polymor-
hisms  associated  with  lower  LDL-C).  Results  showed  that  a
ow  LDL-C  concentration  following  this  random  natural  allo-
ation  decreases  the  risk  of  CHD  by  54.5%  for  each  mmol/L
ecrease  in  LDL-C.  Comparatively,  for  the  same  level  of  LDL-
 decrease,  statin  therapy  started  later  in  life  would  ‘‘only’’
educe  the  risk  of  CHD  by  24.0%  (Fig.  1)  [18].  The  authors
oncluded  that  long-term  exposure  to  a protective  lower
DL-C  beginning  early  in  life  was  associated  with  a  greater
eduction  in  the  risk  of  CHD  than  the  current  practice  of
tarting  to  lower  LDL-C  later  in  life.
Mirroring  these  results,  the  deleterious  effect  of  early
nd  long-term  exposure  to  dyslipidaemia  was  studied  in
he  Coronary  Artery  Risk  Development  in  Young  Adults
CARDIA)  study  [19]. The  effect  of  time-averaged  cumula-
ive  exposure  to  dyslipidaemia  starting  in  young  adulthood
healthy  subjects  at  enrolment,  aged  18—30  years)  was
ssessed  over  a  20-year  period  and  related  to  coronary  cal-
ium  levels  measured  later  in  life  (estimation  based  on
omputed  tomography  scan  by  analysts  blinded  to  partici-
ant  characteristics).  Among  the  3258  participants,  65%  of
atients  were  exposed  to  LDL-C  concentrations  >  100  mg/dL.
he  result  showed  that  exposure  to  high  LDL-C  concentra-
ions  was  strongly  associated  with  coronary  calcium  later
n  life.  Compared  with  in  subjects  with  optimal  LDL-C
oncentrations  < 70  mg/dL,  the  risk  of  coronary  calcium  in
ubjects  exposed  to  slightly  suboptimal  LDL-C  (between
0—99  mg/dL)  was  1.5  times  higher,  although  not  signif-
cantly  different  (95%  conﬁdence  interval  [CI]  0.7—3.3).
ere  not  at  goal  or  abnormal,  data  from  [16].
Diabetes
(n  =  4524)
CVD
(n  =  10,587)
ESC  score  <  5%(n =  4214)
51.9  46.5  63.9
45.3  41.9  55.8
-C: low-density lipoprotein cholesterol; TC: total cholesterol.
ean Union countries (Norway, Sweden, Denmark, Netherlands,
) and Canada.
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Figure 1. Comparative coronary heart disease risk reduction of earlier and later low-density lipoprotein cholesterol (LDL-C) lowering. CI:
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Reproduced with permission from [18].
Nevertheless,  subjects  with  concentrations  even  marginally
higher  (100—129  mg/dL)  had  an  amazing  2.4  times  higher
risk  of  coronary  calcium  (odds  ratio  [OR]  2.4,  95%  CI  1.1—5.3)
and  those  with  concentrations  ≥  160  mg/dL  had  a  5.6  times
higher  risk  (OR  5.6,  95%  CI  2.0—16).
This  indirect  evidence  supports  the  paradigm  of  earlier
and  longer  duration  of  high  LDL-C  management  and  suggests
a  need  for  earlier  screening  and  improved  identiﬁcation  of
patients  who  would  be  eligible  for  pharmacological  inter-
vention.  Regarding  the  pharmacological  management  of
patients  with  high  LDL-C,  the  recently  published  ‘‘American
Heart  Association/American  College  of  Cardiology  guidelines
on  the  treatment  of  blood  cholesterol  to  reduce  atheroscle-
rotic  cardiovascular  risk  in  adults’’  are  very  speciﬁc.  Adults
aged  ≥  21  years  with  primary  LDL-C  ≥  190  mg/dL  should  be
treated  with  statin  therapy  using  a  high  dosage  unless  con-
traindicated  [20].
What is the direct evidence for beneﬁt and
risk of primary prevention with statins?
The  Cochrane  Collaboration  is  a  non-proﬁt  organization
founded  in  1993,  consisting  of  an  international  group  of  close
to  30,000  researchers  from  more  than  100  countries  that
aims  to  independently  review  and  analyse  medical  informa-
tion  in  the  interests  of  evidence-based  medicine  and  public
health.  Since  2011,  the  collaboration  has  developed,  as  a
non-governmental  organization,  an  ofﬁcial  partnership  with
the  World  Health  Organization,  with  a  seat  on  the  World
Health  Assembly  to  provide  input  into  World  Health  Organi-
zation  resolutions  [22,23].
In  the  most  recently  published  Cochrane  systematic
review  and  meta-analysis  of  randomized  clinical  trials
(RCTs),  Taylor  et  al.  concluded  that  the  evidence  showed
that  primary  prevention  with  statins  was  likely  to  be  cost-
effective  and  may  also  improve  patient  quality  of  life  [21].
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iwo  years  earlier,  the  same  authors  had  argued  the  opposite
osition,  contending  that  the  evidence  did  not  advocate  rou-
ine  implementation  of  primary  prevention  with  regard  to
ost-effectiveness,  although  a  reduction  in  all-cause  mor-
ality  and  composite  cardiovascular  events  was  already
bserved  in  this  2011  meta-analysis;  they  expressed  con-
erns  about  the  interpretation  of  the  results  due  to  possible
nder-reports  of  outcomes  and  adverse  events  and  the  inclu-
ion  of  some  patients  with  a history  of  CVD  [24].  What
hanged  between  the  two  publications  was  the  arrival  of
ew  evidence  from  RCTs,  enlarging  the  clinical  data  set  from
4,000  patients/14  RCTs  in  the  2011  meta-analysis  to  57,000
atients/18  RCTs  in  the  2013  review.
What  has  this  new  clinical  evidence  taught  us?  The  most
mportant  ﬁnding  is  that  primary  prevention  with  statins  sig-
iﬁcantly  reduces  all-cause  mortality  by  14%  (OR  0.86,  95%  CI
.79—0.94);  it  also  decreases  the  risk  of  fatal  and  non-fatal
VD  by  approximately  20—25%  (relative  risk  [RR]  0.75,  95%
I  0.70—0.81),  the  risk  of  combined  fatal  and  non-fatal  CHD
vents  (RR  0.73,  95%  CI  0.67—0.80)  and  the  risk  of  combined
atal  and  non-fatal  strokes  (RR  0.78,  95%  CI  0.68—0.89).  More
mportantly,  in  terms  of  cost-effectiveness,  the  correspond-
ng  number  needed  to  treat  (NNT)  for  5  years  to  prevent  one
vent  would  be  fairly  low:  an  NNT  of  96  to  avoid  one  death
rom  all  causes;  an  NNT  of  56  to  prevent  one  CHD  event  (fatal
r  not);  an  NNT  of  35  to  avoid  one  cardiovascular  event  (fatal
r  not);  and  an  NNT  of  only  20  to  prevent  one  stroke  (fatal
r  not).
The  work  conducted  by  the  Cholesterol  Treatment  Tri-
lists’  (CTT)  Collaborators  [25]  showed  results  consistent
ith  and  complementary  to  the  analysis  performed  by
he  Cochrane  collaboration.  This  very  large  individual
atient  data  meta-analysis  included  27  trials  with  approx-
mately  175,000  patients  with  high  LDL-C  concentrations,
hich  compared  statins  versus  control  (22  RCTs)  or  high-
ose  versus  low-dose  statins  (5  RCTs).  The  primary  ﬁnding
n  the  overall  population  was  that  for  each  1.0  mmol/L
192  E.  Bruckert,  J.  Ferrières
Figure 2. Global effects on major vascular events (MVE) per 1.0 mmol/L reduction in low-density lipoprotein (LDL) cholesterol at different
l l; RR:
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eproduced with permission from [25].
eduction  of  LDL-C  by  statin  therapy,  the  risk  of  major  vas-
ular  events  decreased  by  21%  (RR  0.79,  95%  CI  0.77—0.81,
er  1.0  mmol/L).  The  RR  reduction  (RRR)  for  major  vascular
vents  was  25%  (RR  0.75,  95%  CI  0.70—0.80)  when  statins
ere  used  in  patients  without  a  previous  history  of  vascular
isease,  which  was  similar  to  the  RRR  of  20%  (RR  0.80,  95%  CI
.77—0.82)  achieved  for  secondary  prevention  (Fig.  2)  [25].
igniﬁcant  reductions  in  vascular  death  by  15%  and  12%  per
.0  mmol/L  LDL-C  decrease  were  observed  in  the  primary
nd  secondary  prevention  settings,  respectively.  This  mor-
ality  reduction  remained  signiﬁcant  even  after  exclusion
f  patients  with  diabetes  or  CKD  at  baseline.  Interestingly,
he  reduction  in  major  vascular  events  was  also  statisti-
ally  signiﬁcant  in  the  subset  of  patients  with  low  estimated
ardiovascular  risk  at  baseline  (risk  <  10%  at  5  years).
We  therefore  have  strong  evidence  coming  from  large
ell-conducted  meta-analyses  that  primary  prevention  with
tatins  is  beneﬁcial  in  reducing  MACE,  cardiovascular  death
nd  all-cause  mortality  and,  owing  to  the  low  NNTs  observed,
hat  this  therapeutic  strategy  is  cost-effective  [26].
One  should,  however,  consider  the  balance  between
eneﬁt  and  risk  related  to  statin  therapy.  In  the  latest
ochrane  meta-analysis,  there  was  no  overall  difference  in
he  occurrence  of  all  adverse  events  between  the  statin  and
ontrol  groups  (RR  1.00,  95%  CI  0.97—1.03)  and  no  evidence
or  any  serious  harm  induced  by  primary  prevention  with
tatins,  particularly  regarding  the  risk  of  cancer,  haemor-
hagic  stroke  and  rhabdomyolysis.  However,  a  signiﬁcantly
igher  rate  of  diabetes  was  observed  in  the  active  treatment
rm  versus  control  (RR  1.18,  95%  CI  1.01—1.39);  this  corre-
ponded  to  an  absolute  risk  increase  of  0.4%  (2.8%  for  statins
m
l
b relative risk.
ompared  with  2.4%  in  the  control  and  placebo  arms,  respec-
ively),  which  would  correspond  to  a  number  needed  to  harm
NNH)  of  250  patients  treated  with  statins  over  5  years  to
nduce  one  case  of  diabetes.  Similar  ﬁndings  were  observed
n  an  earlier  meta-analysis  performed  among  more  than
0,000  patients,  focusing  on  incidental  diabetes  in  statin
rials  [27].  The  authors  used  a  conservative  pre-speciﬁed  cri-
erion  for  deﬁning  the  incidental  diabetes  cases:  two  glucose
oncentrations  ≥  7.0  mmol/L  in  trials  that  measured  fasting
lucose  every  6  months  and  only  one  value  ≥  7.0  mmol/L  in
rials  that  measured  fasting  glucose  less  frequently  than
 months.  The  risk  of  incident  diabetes  was  1.09  times  higher
ith  statins  (OR  1.09,  95%  CI  1.02—1.17),  corresponding
o  an  NNH  of  255  patients  treated  for  4  years  to  induce
ne  extra  case  of  ‘‘diabetes’’  as  deﬁned  above.  We  can-
ot  therefore  rule  out  the  possibility  that  statin-treated
atients  may  have  an  increased  likelihood  of  diabetes,  but
hen  translating  these  results  in  a  clinically  meaningful  way,
e  should  stress  that  incidental  diabetes  as  deﬁned  in  RCTs
s  only  a  biological  surrogate  for  possible  diabetic  long-term
omplications.  In  other  words,  for  250  patients  treated  over
 years,  one  case  of  hyperglycaemia/diabetes  might  be  due
o  the  statin  use,  but  in  parallel,  you  would  avoid  at  least
wo  deaths  and  prevent  four  CHD  events  and  12  strokes.
Moreover,  in  patients  with  documented  diabetes  at  base-
ine,  irrespective  of  whether  the  patient  has  a  prior  history
f  vascular  disease,  statins  signiﬁcantly  reduce  the  risk  of
yocardial  infarction  or  coronary  death,  coronary  revascu-
arization  and  the  risk  of  stroke  [28].
Regarding  other  biological  abnormalities  possibly  induced
y  the  use  of  statins,  the  Cochrane  review  suggested
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that  primary  prevention  with  statins  might  induce  a
non-signiﬁcant  trend  toward  more  cases  of  liver  enzyme  ele-
vation  (RR  1.16,  95%  CI  0.87—1.54)  but  without  any  increase
in  the  risk  of  clinically  relevant  liver  dysfunction.  However,
in  a  larger  meta-analysis  (close  to  250,000  patients),  includ-
ing  trials  in  primary  and  secondary  prevention,  the  increased
risk  of  transaminase  elevation  associated  with  statins  was
statistically  signiﬁcant  (OR  1.51,  95%  CI  1.24—1.84).  These
results  probably  reﬂect  the  dose-dependent  relationship  of
statins  with  some  speciﬁc  adverse  effects  [29].
The  dose-dependent  relationship  is  also  questioned  for
statin-induced  myotoxicity,  ranging  from  the  asymptomatic
rise  in  creatine  kinase  concentration,  myalgia  and  myositis
to  the  rare  but  severe  rhabdomyolysis.  Whereas  there  was
no  increase  in  myalgia  in  the  Cochrane  primary  prevention
meta-analysis  (RR  1.03,  95%  CI  0.97—1.09),  other  systematic
reviews  have  suggested  that  statin  type  and/or  high  statin
dose  (secondary  prevention)  would  increase  the  risk  in  crea-
tine  kinase  elevation  and  myalgia  by  up  to  four  times  versus
control  [29,30]  and  the  risk  of  rhabdomyolysis  by  three  times
[31].
This  statin-induced  myotoxicity  not  found  in  primary
prevention  trials  and  meta-analyses  may,  however,  have
a  broader  implication  for  clinical  practice  than  increas-
ing  asymptomatic  glycaemia  elevation.  In  the  non-selected
patients  in  our  real-life  practice,  the  incidence  of  skele-
tal  muscle-related  adverse  effects  is  more  important  than
in  RCTs  [32]  and  could  affect  patient  adherence  to  statin
therapy,  thus,  leading  to  a  deleterious  effect  on  the  risk  of
MACE.  The  observed  difference  between  RCTs  and  real-life
uncontrolled  studies  is  likely  to  be  related  to  the  lower  rep-
resentation  in  RCTs  of  patients  with  factors  associated  with
an  increased  risk  of  myopathy  (e.g.  polypharmacy,  concomi-
tant  use  of  ﬁbrates,  use  of  statins  above  recommended  dose,
young  sporty  subjects,  etc.)  [33].  For  instance,  one  trig-
ger  of  symptomatic  myopathy  commonly  seen  in  our  clinical
practice  is  abrupt  intensive  physical  activity  [34].  Statins
were  also  shown  recently  to  increase  exercise-related  mus-
cle  injury  in  marathon  runners  [35].
As  for  severe  chronic  muscle  toxicity,  literature  is  scarce
and  review  is  made  even  more  complex  due  to  the  vari-
ous  deﬁnitions  of  ‘‘myotoxicity’’  used  by  different  Health
Authorities  or  academic  entities  [36].  For  example,  the  US
Food  and  Drug  Administration  deﬁnes  myotoxicity  as  the
presence  of  symptoms  of  myalgia  and  creatine  kinase  >  10
times  the  upper  limit  of  normal,  whereas  the  American
College  of  Cardiology  considers  symptoms  of  myalgia  to
be  sufﬁcient.  In  addition,  the  most  important  barrier  that
clearly  inﬂuences  the  importance  of  statin-induced  severe
myotoxicity  is  the  rarity  of  occurrence.  Large  cohort  stud-
ies  suggest  that  the  incidence  of  rhabdomyolysis  ranges  from
0.44  to  5.4  per  10,000  person-years  with  statin  monotherapy,
corresponding  to  an  NNH  of  23,000  to  induce  one  case  [37].
Another  issue  is  the  difﬁculty  in  diagnosing  and  deﬁnitely
attributing  the  serious  adverse  event  to  the  lipid-lowering
therapy.  For  instance,  immune  myositis  (a  newly  identiﬁed
entity  among  chronic  statin-induced  myopathy)  is  a  rare
adverse  event  with  a  prevalence  not  clearly  established,
and  its  diagnosis  relies  on  a  complex  set  of  clinical,  bio-
logical  and  imaging  criteria.  An  immune  myositis  diagnosis
can  be  suspected  in  case  of  muscle  weakness/atrophy  per-
sisting  for  weeks  or  months  after  statin  discontinuation,
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iopsy  showing  a  predominantly  necrotizing  myopathy  with
inimal  lymphocytic  inﬁltrates  and  positive  anti-HMGCR  (3-
ydroxy-3-methylglutaryl  coenzyme  A  reductase)  antibodies
38,39].
Until  now,  studies  have  failed  to  identify  genetic  vari-
tions  with  large  effects  on  statin  efﬁcacy  or  toxicity.
angravite  et  al.  recently  identiﬁed  six  expression  quanti-
ative  trait  loci  that  interact  with  simvastatin  exposure  and,
specially,  one  locus  associated  with  incidence  of  statin-
nduced  myotoxicity  [40].
hat is the beneﬁt of a moderate versus a
igh-dose of statin started earlier in life in
igh-risk patients?
igh-risk  patients  include  both  high-risk  and  very  high-risk
atients.  According  to  the  European  Society  of  Cardiol-
gy/European  Atherosclerosis  Society  guidelines  [14],  the
ategory  of  high-risk  patients  includes  subjects  with  any  of
he  following:  markedly  elevated  single  risk  factors,  such
s  familial  dyslipidaemia  and  severe  hypertension;  a  cal-
ulated  SCORE  risk  ≥  5%  and  <  10%  for  the  10-year  risk  of
atal  CVD.  The  category  of  very  high-risk  subjects  includes
atients  with  any  of  the  following:  documented  CVD  by  inva-
ive  or  non-invasive  testing  (such  as  coronary  angiography,
uclear  imaging,  stress  echocardiography,  carotid  plaque
n  ultrasound);  previous  myocardial  infarction,  ACS,  coro-
ary  revascularization  (percutaneous  coronary  intervention,
oronary  artery  bypass  graft)  and  other  arterial  revascula-
ization  procedures,  ischaemic  stroke  or  peripheral  arterial
isease;  type  2  diabetes,  type  1  diabetes  with  target  organ
amage  (such  as  microalbuminuria);  moderate-to-severe
KD  (glomerular  ﬁltration  rate  <  60  mL/min/1.73  m2);  a  cal-
ulated  10-year  SCORE  risk  ≥  10%.  For  the  SCORE  risk,  the
0-year  risk  of  fatal  CVD  in  populations  at  high  CVD  risk  is
ased  on  ﬁve  risk  factors  (age,  sex,  smoking,  systolic  blood
ressure  and  total  cholesterol);  to  convert  the  risk  of  fatal
VD  to  the  risk  of  total  (fatal  +  non-fatal)  hard  CVD,  multi-
ly  by  3  in  men  and  4  in  women,  and  by  slightly  less  in  old
eople.
Lessons  from  nature-inherited  traits  that  gave  rise  to
ifelong  high  (familial  hypercholesterolaemia)  or  low  (pro-
rotein  convertase  subtilisin/kexin  type  9  [PCSK9]  loss  of
unction)  LDL  concentrations  showed  that  the  long-term
isks  and  beneﬁts  of  varying  plasma  LDL  concentrations
ay  be  greater  than  the  intervention  trials  suggest  [41].
he  Mendelian  randomization  studies  conducted  by  Ference
t  al.  [18]  and  Cohen  et  al.  [42]  showed  that  the  bene-
t  of  a  lifelong  low  LDL-C  concentration,  as  a result  of
enetic  polymorphisms,  was  three  times  higher  than  that
eported  in  statin  trials  of  only  5—6  years’  duration.  Fur-
hermore,  a  lifelong  39  mg/dL  decrease  in  LDL-C  from  a
CSK9  mutation  was  associated  with  a  54.5%  reduction  in
he  risk  of  CHD.  Conversely,  a  lifelong  34  mg/dL  increase
n  LDL-C  doubles  the  risk  of  coronary  artery  disease  com-
ared  with  in  patients  who  develop  raised  cholesterol  in
ater  adult  life.  Together,  these  ﬁndings  suggest  that  initia-
ion  of  LDL-lowering  throughout  life,  including  in  childhood
nd  adolescence,  and  in  the  primary  prevention  setting  leads
o  a  greater  clinical  impact  in  terms  of  CVD  reduction.
1 E.  Bruckert,  J.  Ferrières
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urthermore,  genetically  mediated  changes  in  LDL-C  are
ikely  to  be  a  better  reﬂection  of  the  cumulative  effect
f  lifelong  exposure  to  differences  in  circulating  LDL-C
ompared  with  measurements  in  adulthood.  Although  the
eneﬁts  of  lifelong  statin  therapy  appear  to  be  incontro-
ertible,  a  question  arises  regarding  the  beneﬁt  of  moderate
ersus  high-doses  of  statins  started  earlier  in  life  in  high-
isk  subjects,  as  there  is  concern  about  the  tolerability  of
igh-doses  of  statin,  as  discussed  above.
Several  trials  have  compared  more  intensive  versus
tandard  statin  regimens  [43,44]  to  determine  whether
igher  reductions  in  LDL-C  safely  lead  to  further  reductions
n  MACE.  Although  the  results  showed  a  trend  in  favour  of
igh-dose  statin  therapy  over  standard-dose  therapy  [45],
ew  studies  had  signiﬁcant  results  for  their  primary  out-
omes  [46,47].
The  whole  discussion  is  complex,  as  we  have  to  take  into
ccount  the  possible  side  effects  with  long-term  statin  treat-
ent  (>  5  years)  and  increased  frequency  of  side  effects  with
igh-doses.  The  fact  that  there  is  a  continuing  debate  is  illus-
rated  by  various  guidelines  in  which  high-intensity  statins
re  recommended  for  some  high-risk  patients  whereas  oth-
rs  are  advised  to  start  at  moderate  doses  (American  College
f  Cardiology/American  Heart  Association)  [20].
ow can we improve primary prevention
n  high-risk patients?
t  has  become  a  priority  to  increase  public  and  physician
wareness  of  the  new  evidence  demonstrating  the  beneﬁt  of
rimary  prevention  with  statins.  An  important  necessity  is  to
urther  explain  the  clinical  beneﬁt  relevance  in  terms  of  NNT
nd  absolute  risk  decrease.  Indeed,  the  RRR  expressed  as  a
ercentage  is  useful  to  describe  the  extent  of  the  efﬁcacy
mong  similar  drugs  or  versus  a  placebo,  but  does  not  reﬂect
he  importance  of  the  clinical  beneﬁt  among  the  whole  arse-
al  of  cardioprotective  drugs.  Other  agents  or  family  of
rugs  are  widely  used  in  the  primary  prevention  of  MACE,
espite  variable  levels  of  evidence  and  larger  NNTs  than
tatins.  The  use  of  aspirin  is  indisputable  for  the  secondary
revention  of  coronary  events  but  is  increasingly  debated
or  primary  prevention  [48],  although  its  use  was  reported
o  reach  up  to  18%  in  patients  at  low  cardiovascular  risk  [49].
or  diabetic  patients,  the  American  Diabetes  Association
nd  the  American  Heart  Association  jointly  recommended
n  2007  that  aspirin  should  be  used  as  a  primary  prevention
trategy  in  those  at  high  cardiovascular  risk  [50],  but  new
vidence  from  inconclusive  trials  has  raised  questions  about
ts  actual  beneﬁt  in  primary  prevention  [51,52].  A  recent
arge  meta-analysis  [53],  including  the  latest  primary  pre-
ention  trials  and  more  than  100,000  patients  followed  for
 mean  duration  of  6  years,  showed  that  aspirin  treatment
educed  total  cardiovascular  events  by  10%  (NNT  =  120).
esults  were  driven  primarily  by  a  signiﬁcant  reduction  in
on-fatal  myocardial  infarction  (NNT  =  162),  without  a sig-
iﬁcant  reduction  in  cardiovascular-related  death  (OR  0.99,
5%  CI  0.85—1.15)  and  at  the  expense  of  an  increased  risk
f  clinically  relevant  bleeding  events  (NNH  = 73).  As  for
tatin  therapy,  the  2013  Cochrane  meta-analysis  demon-
trated  that  the  corresponding  NNTs  were  35  to  prevent
ne  cardiovascular  event  and  56  to  avoid  one  total  CHD
p
W
vajor cardiovascular event in comparable primary prevention popu-
ations for statin therapy, anti-hypertensive therapy and aspirin.
eproduced with permission from [58].
vent.  As  opposed  to  evidence  with  aspirin,  statins  signiﬁ-
antly  reduced  cardiovascular-related  death  (NNT  =  30)  and
ll-cause  death  (NNT  =  96)  [21].
These  results  can  also  be  put  in  perspective  with  anti-
ypertensive  drugs.  Diuretic  and  beta-blocker  therapies
igniﬁcantly  reduce  total  cardiovascular  events,  but  the
NTs  would  be  at  least  twice  as  high  as  for  statins,  with
alues  between  86  for  diuretics  and  140  for  beta-blockers.
etwork  meta-analyses  also  suggest  that  the  effect  size
n  morbidity  and  mortality  varies  markedly  with  the  class
f  anti-hypertensives.  The  only  agents  to  have  consistently
roved  reduction  in  all-cause  death  (RRR  ∼  10%)  in  direct
r  through  network  comparisons  are  diuretics  [54,55]. In
ontrast,  beta-blockers  did  not  reduce  all-cause  deaths  (RR
.99,  95%  CI  0.88—1.11)  or  CHD  events  in  a  recent  Cochrane
eta-analysis  [56].
Thus,  despite  explicitly  excluding  patients  with  LDL-
 >  130  mg/dL  and  including  large  numbers  of  women  (who
ave  lower  event  rates  than  men),  the  absolute  risk
eductions  observed  in  the  JUPITER  trial  [57]  and  the
oncomitant  NNT  values  are,  if  anything,  superior  to  those
or  statin  therapy  in  the  primary  prevention  of  vascular
vents  among  hyperlipidaemic  men  or  the  prophylactic  use
f  anti-hypertensive  or  anti-thrombotic  therapies  among
iddle-aged  and  older  men  and  women  (Fig.  3) [58].
Finally,  the  robustness  of  evidence  is  highest  with  statin
se  in  primary  prevention  compared  with  any  other  class  of
edication  routinely  prescribed  to  prevent  MACE.
The  purpose  of  the  review  is  not  to  add  confusion  to  the
urrent  controversy  about  which  class  of  medication  should
e  used  for  primary  prevention  of  cardiovascular  events,
ut  rather  to  question  the  reasons  why  statins  are  used  less
requently  than  other  drugs  in  patients  at  risk.
hy is primary prevention in high-risk
atients not adequately implemented?
hatever  the  type  of  primary  care  pharmacological  inter-
ention,  one  commonly  debated  question  before  routinely
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implementing  primary  prevention  is  the  pharmaco-economic
aspect.  One  may  argue,  for  example,  that  statin  therapy  is
expensive  and  that  prescribing  it  to  all  high-risk  patients
would  represent  an  unnecessary  ﬁnancial  burden  to  the
public  health  system.  We  should,  however,  consider  two
dimensions  of  the  pharmaco-economic  assessment.
The  ﬁrst  dimension  is  at  ‘‘patient  and  disease  level’’.
What  is  the  cost-effectiveness  of  a  given  treatment  versus
a  placebo/non-treated  control  if  prescribed  to  all  patients
who  actually  deserved  to  be  treated?  The  answer  to  this
question  relies  primarily  on  RCTs  and  meta-analyses  of
trials  conducted  in  this  population.  If  the  societal  cost
induced  by  the  adverse  event  (e.g.  MACE)  is  higher  than
the  overall  treatment  cost,  and  if  the  drug  was  proven
to  be  effective  in  RCTs,  there  is  a  good  chance  that  the
pharmaco-economic  evaluation  would  favour  the  preven-
tion  strategy  over  no  treatment.  The  lower  the  NNT  the
higher  this  probability  is.  We  have  shown  in  this  example
that  primary  prevention  with  statins  is  likely  to  be  cost
saving  if  prescribed  to  high-risk  patients,  at  least  as  much
as  (and  probably  more  than)  primary  prevention  with  anti-
hypertensives  or  aspirin  (the  latter  not  being  cost-effective,
with  no  evidence  for  efﬁcacy  and  a  low  NNH  for  bleed-
ing).
The  second  dimension  is  at  the  general  population  level.
The  pharmaco-economic  evaluation  is  more  difﬁcult  to  con-
duct  and  varies  according  to  regional  speciﬁcities.  One
should  consider  the  prevalence  of  the  risk  factor  in  the  given
population  (e.g.  USA  versus  European  Union),  costs  related
to  screening  the  population,  probability  that  the  treat-
ment  is  given  to  the  appropriate  patients,  adherence  to  the
prescribed  treatment,  etc.  [59].  Brieﬂy,  the  epidemiologi-
cal  speciﬁcities  and  real-life  local  practice/habits  become
important  determinants  in  assessing  the  cost-effectiveness
of  a  primary  prevention  strategy.  For  instance,  in  France,  the
direct  cost  related  to  statin  prescription  is  one  of  the  high-
est  among  reimbursed  drugs,  with  yearly  per-patient  costs
ranging  between  85  D  and  512  D  in  2010  [60].  The  average
yearly  cost  is  therefore  undoubtedly  higher  than  for  some
other  primary  care  drugs  (e.g.  thiazide  diuretics)  but  when
comparing  the  total  drug  expenditures,  the  latest  French
National  Health  Insurance  report  showed  that  hypertensives
expenses  amount  to  more  than  twice  those  incurred  with
lipid-lowering  therapy  used  for  primary  prevention  (Fig.  4)
[61].
The  discrepancy  between  average  drug  cost  and  actual
expenditure  is  multifactorial:
t
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Figure 4. Expenditures associated with diabetes, arterial hypertensio
Data taken from [61].ith  statins  195
a combination  of  anti-hypertensives  is  often  required  to
control  HBP;
there  is  a  substantial  rate  of  overtreatment  with  anti-
hypertensives,  and;
evidence-based  classes,  such  as  diuretics,  are  not  consid-
ered  as  ﬁrst-line  therapy  [62].
Regarding  statin-based  therapy,  it  is  also  clear  that  the
ame  inappropriate  practices  would  also  compromise  the
ost-effectiveness  of  primary  prevention.  Efforts  should  still
e  made  to  both  avoid  underuse  and  overuse  of  statins.  In
he  UK,  a  recent  large  cohort  study  showed  that  there  was
 substantial  proportion  of  overuse  in  low-CVD  risk  patients
nd  underuse  in  high  CVD  risk  patients,  with  large  variations
etween  general  practices  ranging  from  8.2%  to  61.5%  statin
se  in  high-risk  patients  and  from  2.1%  to  29.1%  in  low-risk
atients  [63].
These  misuses  were  shown  to  offset  the  cost-
ffectiveness  of  statin-based  primary  prevention.  Greving
t  al.  [64]  showed  in  a  pharmaco-economic  model  that  the
ost-effectiveness  of  statins  was  not  only  related  to  drug
ost,  but  also  to  variables,  such  as  non-adherence  rates  and
he  ‘‘time  horizon’’  (the  time  after  which  the  evaluation
s  done).  Basically,  the  higher  the  risk,  the  better  the
dherence  and  the  longer  the  observation  period  (lifelong
ime  horizon),  the  lower  the  cost-effectiveness  would  be
Fig.  5) By  comparison,  primary  prevention  would  not  be
ost-effective  in  low-risk  cardiovascular  patients  despite
owering  generic  statin  costs.
The  model  was  also  sensitive  to  the  projected  efﬁcacy
f  statins  in  a real-life  setting.  We  showed  in  a  recently
ublished  large  case-control  study  that  the  magnitude  of
eduction  of  non-fatal  ACS  for  statins  observed  in  real-
orld  French  practice  was  similar  to  that  found  in  RCTs
65]. After  adjusting  for  baseline  risk  factors,  prior  expo-
ure  to  statin  therapy  was  signiﬁcantly  associated  with  an
pproximately  30%  (27—33%)  RRR  for  a  ﬁrst  non-fatal  ACS
ompared  with  non-users;  this  compared  favourably  with
he  33%  RRR  in  non-fatal  CHD  observed  in  the  2013  Cochrane
eta-analysis  discussed  earlier.  Importantly,  consistent  with
he  pharmaco-economic  modelling  by  Greving  et  al.,  we
ound  that  targeting  the  highest  risk  group  for  a  longer  total
tatin  exposure  would  be  the  most  clinically  effective,  and
hus,  cost-effective,  strategy  (Table  2)  [65].
Apart  from  the  objective  barriers  to  the  implementation
f  primary  prevention  (clinical  evidence,  pharmaco-
conomic  constraints),  some  subjective  components  should
n and hypercholesterolaemia (2011). HBP: high blood pressure.
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Figure 5. Sensitivity analysis: cost-effectiveness results for different risk and time horizons. ICER: incremental cost-effectiveness ratio;
QALY: quality-adjusted life years (calculated by multiplying the time a person remained in a certain health state by the utility associated with
that particular health state and subsequent summing up over all health states). *The 10-year vascular risk of fatal and non-fatal myocardial
infarction and stroke was estimated from the expected number of ﬁrst vascular events over the ﬁrst 10 years divided by the total number
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e  highlighted.  We  showed  in  France  that  there  were
arked  differences  between  physicians’  and  patients’
eliefs  regarding  the  risk  of  hypercholesterolaemia,  which
ubsequently  induced  a  blurred  perception  of  the  dis-
ase  [66],  and  it  was  demonstrated  by  an  Italian  group
hat  physicians’  beliefs  were  independently  correlated  with
ipoprotein-lowering  therapy  prescription  rate  and  hyper-
holesterolaemia  control  over  a  3-year  period  in  high-risk
iabetic  patients  [67].  Thus,  we  should  also  take  into
ccount  these  subjective  variables  in  our  educational  and
wareness  programmes,  to  appropriately  implement  pri-
ary  prevention  in  high-risk  patients.  This  approach  is  also
ssential  to  improve  patient  adherence  to  statins,  which  is
 key  determinant  associated  with  the  effectiveness  of  all
harmacological  therapies.
a
s
o
tevents by age group and sex were obtained from a record linkage
ascular disease were examined, from 1% to 30%.
Retrospective  database  analyses  have  revealed  that  50%
f  patients  receiving  statins  discontinue  therapy  after  1  year
f  treatment  [68].  Studies  also  suggest  that  patient  adher-
nce  to  statin  therapy  is  suboptimal,  ranging  from  30%  to  70%
n  treated  patients,  and  that  persistence  among  those  newly
rescribed  statins  is  low  [69—71].  Poor  adherence  to  statin
herapy  is  associated  with  adverse  health  outcomes,  includ-
ng  higher  hospitalization  rates  and  increased  non-pharmacy
edical  costs  [72—74].
Some  studies  have  investigated  data  from  various  pub-
ications,  analysing  the  sociodemographic,  medical  history
nd  health  care  utilization  variables  reliably  associated  with
tatin  non-adherence  [68,75]. They  identiﬁed  a  broad  range
f  possible  predictors,  such  as  demographics,  physician  fac-
ors,  health  beliefs  of  patients,  complexity  of  medication
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Table  2  Assessment  of  the  association  between  statin  use  and  occurrence  of  ﬁrst  acute  coronary  syndrome,  stratiﬁed
by  duration  of  current  statin  use  and  risk  score,  data  from  [65].
ACS  cases
(n  =  2234)
No  ACS  controls
(n  =  2236)
Crude  matched
OR  (95%  CI)
Adjusted  matcheda
OR  (95%  CI)
Duration  of  current  statin  use
≤ 1  year  68  (3.0)  73  (3.3)  0.86  (0.61—1.20)  0.82  (0.56—1.19)
>  1  to  <  4  years  212  (9.5)  275  (12.3)  0.70  (0.58—0.86)  0.64  (0.51—0.79)
≥  4  years 133  (6.0) 191  (8.5)  0.64  (0.51—0.81)  0.63  (0.49—0.82)
Statin  use  in  24  months
Low-risk  quartileb 65  (20.6) 186  (23.1) 0.81  (0.59—1.12)  0.83  (0.60—1.16)
Quartile  2b 98  (21.5) 157  (25.9) 0.68  (0.50—0.93)  0.73  (0.53—1.00)
Quartile  3b 137  (22.2)  149  (28.5)  0.66  (0.50—0.88)  0.70  (0.53—0.94)
High-risk  quartileb 183  (21.6)  92  (30.5)  0.55  (0.40—0.75)  0.60  (0.43—0.83)
Data are number exposed (%), unless otherwise indicated. ACS: acute coronary syndrome; CI: conﬁdence interval; OR: odds ratio.
a Obtained by multiple conditional logistic regression, including smoking, hypertension, body mass index, physical activity, diabetes
mellitus and alcohol consumption; matching variables were sex, age, number of visits to a general practitioner in the year preceding
the index date, date of consultation and personal history of non-cardiovascular chronic disease.
b Score risk obtained by multiple regression analyses, including body mass index, physical activity, smoking habits, alcohol consumption,
hypertension, diabetes, hypercholesterolaemia and geographical origin of patients.
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Rregimen,  severity  of  disease,  medication  side  effects  and
systemic  barriers,  which  are  probably  not  unique  to  statins
and  may  represent  a  core  set  of  easily  obtainable  variables
that  should  be  used  to  identify  individuals  and  populations
at  risk  of  poor  adherence  to  other  cardiovascular  medi-
cations  (anti-hypertensives,  aspirin,  anti-diabetics).  In  the
selected  studies,  adherence  to  statin  therapy  was  mea-
sured  using  either  a  validated  self-report  scale  or  objective
measures  of  adherence,  including  medication  reﬁll  data,
pill  counts  or  electronic  medication  monitoring.  Few  stud-
ies  assessed  patients’  perceptions  of  statin  therapy  with
respect  to  non-adherence  [76,77].  Interestingly,  the  three
most  commonly  cited  reasons  for  primary  non-adherence
were  general  concerns  about  the  medication,  a  preference
for  lifestyle  modiﬁcations  [78]  and  fear  of  side  effects.  Par-
ticular  attention  should  be  paid  to  younger  individuals  and
those  who  are  taking  statins  as  part  of  primary  prevention,
as  these  groups  had  the  highest  rates  of  non-adherence  [75].
As  reasons  for  primary  non-adherence  to  statin  ther-
apy  are  multifactorial,  individualized  interventions  may
be  warranted  to  improve  adherence  to  statin  therapy.  It
may  be  also  helpful  to  institute  interventions  at  the  time
of  the  initial  prescription  in  particular.  Gaining  a  bet-
ter  understanding  of  the  range  of  underlying  motivations
for  discontinuing  therapy  is  critical  for  designing  effec-
tive  interventions.  Identifying  the  types  and  sources  of
information  patients  use  to  learn  about  statins  and  their
perceptions  of  cardiovascular  risk  factors  could  also  improve
clinician—patient  communication  about  statins.
ConclusionHypercholesterolaemia  is  a  well-known  cardiovascular  risk
factor,  which  is  asymptomatic  compared  with  HBP  or  dia-
betes.  Although  lifestyle  interventions,  such  as  smoking
cessation,  weight  loss  and  physical  activities,  are  the  ﬁrstherapeutic  approach  during  primary  prevention,  a  pharma-
ological  intervention  should  be  set  up  in  patients  at  high
ardiovascular  risk.  To  date,  there  is  sufﬁcient  proof  com-
ng  from  RCTs  to  remove  all  barriers  to  the  prescription
f  effective  therapeutic  measures,  including  the  adminis-
ration  of  statins.  Side  effects  are  rare  and  most  are  not
erious.  The  threshold  of  prescription  is  actually  related  to
he  countries’  incomes.  Compliance  is  a  major  problem  in
he  success  of  primary  prevention.  All  elements  that  affect
ompliance,  linked  either  to  the  patients  or  to  the  media
nvironment,  have  serious  consequences  for  public  health.
roviding  transparent  and  objective  awareness  should  stim-
late  interest  in  following  therapeutic  guidelines  based  on
ll  available  evidence.
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